AMA Journal of Ethics^®

Modeling how technology assessment fits into cost-effectiveness frameworks can broaden the range of options for improving health equity.

Dr Caleb Alexander examines the US Food and Drug Administration's controversial decision to approve aducanumab for the treatment of Alzheimer's Disease.

A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches.

“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.

Overall utilization of the few biosimilars currently available to patients has been limited.

Advances in CEA methodology might integrate equity at the cost of transparency.

Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients.

Traditional curricular focus areas are insufficient for preparing future clinicians to function in a rapidly evolving health care system.

Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.

Burn care physicians must walk a fine line between providing individualized care and applying population-based quality metrics.